{"id":13852,"date":"2026-06-01T17:10:00","date_gmt":"2026-06-01T15:10:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=b8bbeab36b0355402c0adcec7a1e5643"},"modified":"2026-06-01T17:10:00","modified_gmt":"2026-06-01T15:10:00","slug":"ge-healthcare-focuses-on-expanding-access-to-nuclear-medicine-through-ai-radiopharmaceutical-and-imaging-innovations","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=13852","title":{"rendered":"GE HealthCare Focuses on Expanding Access to Nuclear Medicine Through AI, Radiopharmaceutical and Imaging Innovations"},"content":{"rendered":"<ul class=\"bwlistdisc\">\n<li>\nNuclear medicine is reaching an inflection point as advances in imaging, theranostics and radiopharmaceuticals help accelerate clinical adoption<\/li>\n<li>\nAt #SNMMI26, GE HealthCare is showcasing solutions designed to expand access, streamline workflows and support precision care across care pathways<\/li>\n<\/ul><p>CHICAGO--(BUSINESS WIRE)--As theranostics adoption accelerates<sup>i<\/sup> and radiopharmaceutical demand grows,<sup>ii<\/sup> healthcare systems are under increasing pressure to scale nuclear medicine operations while improving diagnostic confidence and workflow efficiency. At the 2026 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, GE HealthCare showcases its latest technologies and AI-enabled workflows to help support precision care across care pathways.<\/p><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260601878700\/en\/1907724\/5\/GE_HealthCare_logo_NEW_March_2023.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260601878700\/en\/1907724\/22\/GE_HealthCare_logo_NEW_March_2023.jpg\" \/><\/a><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260601878700\/en\/1907724\/5\/GE_HealthCare_logo_NEW_March_2023.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260601878700\/en\/1907724\/21\/GE_HealthCare_logo_NEW_March_2023.jpg\" \/><\/a><p>\nNuclear medicine is undergoing rapid expansion as healthcare systems increase adoption of theranostics, broaden radiopharmaceutical access and invest in precision diagnostics and targeted therapies. This momentum is also evident in global nuclear medicine market projections, which anticipate growth from approximately $7.8 billion in 2024 to more than $30.7 billion by 2034.<sup>iii<\/sup><\/p><p>\n\u201cNuclear medicine is moving from early innovation to large-scale clinical implementation,\u201d shares Jean-Luc Procaccini, President and CEO, Molecular Imaging and Computed Tomography (MICT), GE HealthCare. \u201cHealthcare systems need technologies and workflows that help expand access, improve efficiency and support more confident clinical decision-making as theranostics adoption and precision care evolve.\u201d<\/p><p>\n<b>Turning convergence into clinical reality<\/b><\/p><p>\nGrowing demand for precision diagnostics and targeted therapies is helping accelerate the evolution of nuclear medicine. Advances in radiopharmaceuticals and imaging technologies help clinicians diagnose disease, improve treatment planning and expand access to personalized care. As adoption increases, healthcare systems are also facing new operational challenges \u2013 including how to scale infrastructure, streamline workflows and expand patient access beyond traditional hospital settings.<sup>iv<\/sup><\/p><p>\nRising prevalence of chronic diseases is further driving demand for timely and advanced diagnoses and targeted treatment approaches. Fortunately, new care delivery models are already taking shape across care pathways. These models are increasingly enabled by advances in radiopharmaceuticals that expand access to PET imaging and support more scalable, routine clinical use across care settings.<\/p><p>\nEarly examples of this shift are emerging to reach patients beyond traditional hospital environments:<\/p><ul class=\"bwlistdisc\">\n<li>\n<b>Cardiology<\/b>: GE HealthCare\u2019s Flyrcado\u2122 (flurpiridaz F 18 injection) is helping expand access to PET myocardial perfusion imaging (MPI) through a ready-to-use, unit-dose model designed for routine clinical workflows. The company is also collaborating with channel partners to accelerate the adoption of cardiac PET MPI in community settings while mobile imaging models are extending access beyond traditional hospital environments, bringing precision PET imaging to sites that may not otherwise have access.<\/li>\n<li>\n<b>Neurology<\/b>: As demand for Alzheimer\u2019s diagnostics grows,<sup>v<\/sup> GE HealthCare offers Vizamyl\u2122 (flutemetamol F 18 injection) and quantitative tools such as MIMneuro\u2122 to support more consistent amyloid PET interpretation and clinical decision-making. These technologies can help providers integrate amyloid imaging more efficiently into routine neurological care pathways.<\/li>\n<li>\n<b>Oncology<\/b>: Theranostics adoption is also accelerating,<sup>i<\/sup> causing healthcare systems to seek more standardized approaches to imaging, treatment planning and response assessment. GE HealthCare\u2019s StarGuide SPECT\/CT, Intelligent Radiation Therapy (iRT) and MIM portfolio are designed with these needs in mind \u2013 helping simplify whole-body tumor burden assessment, streamline workflows and support more consistent treatment planning across care settings.\n<ul class=\"bwlistcircle\">\n<li>\nThese capabilities also support GE HealthCare\u2019s vision for Adaptive Theranostics\u2122 \u2013 a connected, data-driven approach that integrates molecular imaging, quantitative analysis and multidisciplinary workflows to help tailor therapy decisions over time.<\/li>\n<\/ul><\/li>\n<\/ul><p>\n\u201cThis is an exciting moment for nuclear medicine because we are moving beyond simply detecting disease to truly understanding its biology and behavior,\u201d says Dr. Munir Ghesani, MD, FACNM, FACR, FSNMMI, Chief Medical Officer at United Theranostics and System Chief of Nuclear Medicine at the Mount Sinai Health System in New York. \u201cTechnologies that combine advanced imaging, quantitative analysis and innovative radiopharmaceuticals are helping clinicians make more informed decisions earlier in the care pathway \u2013 ultimately improving how we diagnose, treat and monitor patients.\u201d<\/p><p>\nGE HealthCare\u2019s nuclear medicine portfolio spans imaging systems, AI-enabled software and pharmaceutical diagnostics designed to help clinicians support the full patient journey \u2014 from detection and diagnosis through therapy planning and monitoring.<\/p><p>\n<b>Translating rapid innovation into real-world clinical impact<\/b><\/p><p>\nAt SNMMI 2026, GE HealthCare is highlighting key technologies and software designed to help healthcare systems scale precision imaging, theranostics and quantitative analysis across clinical and research settings:<\/p><p>\n<i>Advanced imaging technologies <\/i>\u2013<\/p><ul class=\"bwlistdisc\">\n<li>\n<b>MIM<\/b> <b>KineticID<\/b>\u2122:<sup>vi<\/sup><b> <\/b>Advanced <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.gehealthcare.com%2Fen-us%2Fabout%2Fnewsroom%2Fpress-releases%2Fge-healthcare-advances-4d-dynamic-pet-imaging-with-u-s-fda-510-k-submission-of-mim-kineticid-designed-to-bring-quantitative-insight-to-disease-assessment&amp;esheet=54544245&amp;newsitemid=20260601878700&amp;lan=en-US&amp;anchor=510%28k%29-pending+software&amp;index=1&amp;md5=915ec8347c419d4b3865f3d61b5e6f1c\" rel=\"nofollow\" shape=\"rect\">510(k)-pending software<\/a> designed for dynamic PET imaging and kinetic modeling, enabling quantitative, time-based analysis of radiotracer behavior to support more informed clinical and research decisions.<\/li>\n<li>\n<b>MIM LesionID\u2122 Pro<\/b>: Recently <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.gehealthcare.com%2Fen-us%2Fabout%2Fnewsroom%2Fpress-releases%2Fge-healthcare-receives-fda-510k-clearance-for-mim-lesionid-pro-helping-transform-whole-body-tumor-burden-analysis&amp;esheet=54544245&amp;newsitemid=20260601878700&amp;lan=en-US&amp;anchor=510%28k%29+cleared+by+the+U.S.+FDA&amp;index=2&amp;md5=5b153a155c50b1591cf9e3cd68582de8\" rel=\"nofollow\" shape=\"rect\">510(k) cleared by the U.S. FDA<\/a>, this AI-powered software automates whole-body tumor burden analysis, reducing the need for manual lesion segmentation, physiologic uptake removal, or multi-image registration while enabling fast access to quantitative insights.<\/li>\n<li>\n<b>Omni Legend<\/b>:<b> <\/b>GE HealthCare\u2019s fastest-selling PET\/CT platform, now with more than 500 installations worldwide.<sup>vii<\/sup> Its high-sensitivity design supports faster scans,<sup>viii<\/sup> improved image quality and enhanced lesion detectability.<sup>ix<\/sup> Omni Legend also includes Precision DL deep learning image processing.<\/li>\n<li>\n<b>StarGuide<\/b>: A digital SPECT\/CT platform featuring 12 CZT detectors and optimized for certain theranostic procedures, enabling high-quality 3D imaging, short scan times and quantitation.<\/li>\n<li>\n<b>MINItrace Magni<\/b>:<sup>x<\/sup> A compact cyclotron solution designed to simplify onsite production of PET tracers and radiometals, including Gallium-68, helping expand radiopharmaceutical access and support more localized production and personalized care delivery.<\/li>\n<\/ul><p>\n<i>Radiopharmaceuticals and imaging agents <\/i>\u2013<\/p><ul class=\"bwlistdisc\">\n<li>\n<b>Flyrcado<\/b>: A PET imaging agent that helps doctors evaluate myocardial ischemia and infarction in people with known or suspected coronary artery disease, including during exercise stress tests.<\/li>\n<li>\n<b>DaTscan<\/b>\u2122<b> <\/b>(ioflupane I\u2011123 injection): A proven neurological diagnostic radiopharmaceutical \u2013 celebrating 25 years in the global market \u2013 to visualize striatal dopamine transporters assisting in the evaluation of patients with suspected Parkinsonian syndromes (PSs) and suspected dementia with Lewy bodies (DLB).<\/li>\n<li>\n<b>Cerianna<\/b>\u2122 (fluoroestradiol F 18 injection): A PET radiopharmaceutical used to detect estrogen receptor (ER)-positive lesions as an adjunct to biopsy in patients with recurrent or metastatic breast cancer.<\/li>\n<li>\n<b>Vizamyl<\/b>: A PET imaging agent used to estimate amyloid beta neuritic plaque density in adults with cognitive impairment to support evaluation of Alzheimer\u2019s disease and other causes of cognitive decline, and to help inform selection of patients for amyloid beta-directed therapy as described in the prescribing information of the therapeutic products.<\/li>\n<\/ul><p>\nTogether, these imaging technologies and agents are designed to support more scalable, data-driven and personalized nuclear medicine workflows across care pathways.<\/p><p>\n<b>Preparing the ecosystem for the next decade of growth<\/b><\/p><p>\nAs nuclear medicine adoption continues to grow, healthcare systems are increasingly focused on the operational requirements needed to support broader clinical use \u2013 including infrastructure, workflow standardization, radiopharmaceutical access and scalable decision support. <sup>xi<\/sup><\/p><p>\nQuantification and advanced imaging analytics are expected to play an increasingly important role in this evolution, particularly in neurodegenerative disease and theranostics, where more standardized interpretation and longitudinal assessment may help advance consistency across sites and clinicians.<\/p><p>\nOne way GE HealthCare is aiming to advance this evolution is through Adaptive Theranostics \u2013 a model that combines molecular imaging, quantitative analytics and connected clinical workflows to help clinicians personalize radioligand therapy decisions across treatment cycles. By supporting more consistent quantification, longitudinal assessment and multidisciplinary collaboration, Adaptive Theranostics is designed to help healthcare systems scale precision care as theranostics adoption grows.<\/p><p>\n\u201cAs molecular imaging continues to scale, success will depend on more than individual products \u2013 it requires building the ecosystem around them,\u201d says Eric Ruedinger, Vice President and General Manager, Pharmaceutical Diagnostics (PDx), USCAN, GE HealthCare. \u201cWe\u2019re focused on enabling that ecosystem end-to-end \u2013 from tracer development and manufacturing to expanding access, integrating workflows and advancing the tools that support confident, consistent decision-making \u2013 so precision care can move from promise to sustained, everyday practice.\u201d<\/p><p>\nSNMMI 2026 represents a pivotal moment for the field \u2013 where decades of innovation are converging with new care models and expanding access to redefine how nuclear medicine is delivered.<\/p><p>\nAs these capabilities continue to scale, nuclear medicine is increasingly positioned as a cornerstone of precision medicine \u2013 enabling clinicians to visualize the biology of disease, tailor therapies to individual patients and monitor treatment response.<\/p><p>\nTo learn more about GE HealthCare\u2019s full suite of nuclear medicine solutions, please visit <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.gehealthcare.com%2F&amp;esheet=54544245&amp;newsitemid=20260601878700&amp;lan=en-US&amp;anchor=gehealthcare.com&amp;index=3&amp;md5=53d6c289798e130b9566870956cef6a9\" rel=\"nofollow\" shape=\"rect\">gehealthcare.com<\/a>.<\/p><p>\n<b>About GE HealthCare Technologies Inc.<\/b><\/p><p>\nGE HealthCare is a leading global healthcare solutions provider of advanced medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions that help clinicians tackle the world\u2019s most complex diseases. Serving patients and providers for 130 years, GE HealthCare is delivering bold innovations designed for the next era of medicine across its Advanced Imaging Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics segments to help clinicians deliver more personalized, precise patient care. We are a $20.6 billion business with approximately 54,000 colleagues working to create a world where healthcare has no limits.<\/p><p>\nGE HealthCare is proud to be among <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ffortune.com%2Franking%2Fworlds-most-admired-companies%2F&amp;esheet=54544245&amp;newsitemid=20260601878700&amp;lan=en-US&amp;anchor=2026+Fortune+World%26%238217%3Bs+Most+Admired+Companies%26%238482%3B.&amp;index=4&amp;md5=826a444c7f7a80548b28dcd85758e65a\" rel=\"nofollow\" shape=\"rect\">2026 <i>Fortune<\/i> World\u2019s Most Admired Companies\u2122.<\/a><\/p><p>\nFollow us on<a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fgehealthcare&amp;esheet=54544245&amp;newsitemid=20260601878700&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=5&amp;md5=913ff04757ffed9df124d443883c4a88\" rel=\"nofollow\" shape=\"rect\"> LinkedIn<\/a>, <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2FGEHealthCare%2F&amp;esheet=54544245&amp;newsitemid=20260601878700&amp;lan=en-US&amp;anchor=Facebook&amp;index=6&amp;md5=6aa0c385fac043b189a7ebbcef4075ca\" rel=\"nofollow\" shape=\"rect\">Facebook<\/a>, <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.instagram.com%2Fgehealthcare%2F&amp;esheet=54544245&amp;newsitemid=20260601878700&amp;lan=en-US&amp;anchor=Instagram&amp;index=7&amp;md5=503865cbf45ba18d2993f33352ebc0fb\" rel=\"nofollow\" shape=\"rect\">Instagram<\/a>, or visit our website for our <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.gehealthcare.com%2Fabout%2Fnewsroom&amp;esheet=54544245&amp;newsitemid=20260601878700&amp;lan=en-US&amp;anchor=latest+news&amp;index=8&amp;md5=9005aa53063fb94dd26275c90aca7e1f\" rel=\"nofollow\" shape=\"rect\">latest news<\/a> and <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.gehealthcare.com%2Finsights%3FshowPopup%3Dfalse&amp;esheet=54544245&amp;newsitemid=20260601878700&amp;lan=en-US&amp;anchor=perspectives&amp;index=9&amp;md5=ee3723663dfd40850b2bed0ac6050e9a\" rel=\"nofollow\" shape=\"rect\">perspectives<\/a>.<\/p><p>\n<b>Important Safety Information<\/b><\/p><p>\n<b>Cerianna\u2122 (fluoroestradiol F 18 injection)\n<br\/><\/b><b>Indication and Usage:\n<br\/><\/b>Cerianna is a radioactive diagnostic agent indicated for use with positron emission tomography (PET) imaging for the detection of estrogen receptor (ER)-positive lesions as an adjunct to biopsy in patients with recurrent or metastatic breast cancer.\n<br\/><b>Limitations of Use:\n<br\/><\/b>Tissue biopsy should be used to confirm recurrence of breast cancer and to verify ER status by pathology. Cerianna is not useful for imaging other receptors such as HER2 or progesterone receptor (PR).\n<br\/><b>Contraindications:\n<br\/><\/b>None.\n<br\/><b>Adverse Reactions:\n<br\/><\/b>In Clinical Trials (n=1207) the most common adverse reactions seen occurred at a rate &lt; 1% were injection-site pain and dysgeusia.<\/p><p>\nTo report SUSPECTED ADVERSE REACTIONS, contact GE HealthCare at 800-654-0118 or the FDA at 800-FDA-1088 or <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.fda.gov%2Fmedwatch&amp;esheet=54544245&amp;newsitemid=20260601878700&amp;lan=en-US&amp;anchor=www.fda.gov%2Fmedwatch&amp;index=10&amp;md5=db3e32e47c540407500cfafad0985942\" rel=\"nofollow\" shape=\"rect\">www.fda.gov\/medwatch<\/a>.\n<br\/>For full prescribing information, please visit:\n<br\/><a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.gehealthcare.com%2F-%2Fjssmedia%2FGEHC%2FUS%2FFiles%2FProducts%2FNuclear-Imaging-Agents%2FCerianna%2Fcerianna-pi&amp;esheet=54544245&amp;newsitemid=20260601878700&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.gehealthcare.com%2F-%2Fjssmedia%2FGEHC%2FUS%2FFiles%2FProducts%2FNuclear-Imaging-Agents%2FCerianna%2Fcerianna-pi&amp;index=11&amp;md5=c0e098f15570bf2f0436613d51127e4a\" rel=\"nofollow\" shape=\"rect\">https:\/\/www.gehealthcare.com\/-\/jssmedia\/GEHC\/US\/Files\/Products\/Nuclear-Imaging-Agents\/Cerianna\/cerianna-pi<\/a><\/p><p>\n<b>DaTscan\u2122 (ioflupane I<\/b>\u2011<b>123 injection)\n<br\/><\/b><b>Indication and Usage:\n<br\/><\/b>DaTscan is indicated as an adjunct to other diagnostic evaluations for striatal dopamine transporter visualization using single photon emission computed tomography (SPECT) brain imaging in adult patients with suspected Parkinsonian syndromes (PS) or suspected dementia with Lewy bodies (DLB).\n<br\/><b>Contraindications:\n<br\/><\/b>Known hypersensitivity to ioflupane I\u2011123 or its components.\n<br\/><b>Adverse Reactions:\n<br\/><\/b>In clinical trials, headache, nausea, vertigo, dry mouth, or dizziness were reported at a rate of 1% or less. In postmarketing experience, hypersensitivity reactions and injection-site pain have been reported.<\/p><p>\nTo report SUSPECTED ADVERSE REACTIONS, contact GE Healthcare at 800 654 0118 (option 2, then option 1) or the FDA at 800 FDA 1088 or <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.fda.gov%2Fmedwatch&amp;esheet=54544245&amp;newsitemid=20260601878700&amp;lan=en-US&amp;anchor=www.fda.gov%2Fmedwatch&amp;index=12&amp;md5=e9cd1a2f57a80ecfb1cccfaae3991d36\" rel=\"nofollow\" shape=\"rect\">www.fda.gov\/medwatch<\/a>.\n<br\/>Prior to DaTscan administration, please read the <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.gehealthcare.com%2Fcontent%2Fdam%2Fgehc%2Fglobal%2Fproducts%2Fmolecular-imaging-agents%2Fdatscan%2Fdocuments%2FDaTscan-Prescribing-Information.pdf&amp;esheet=54544245&amp;newsitemid=20260601878700&amp;lan=en-US&amp;anchor=full+Prescribing+Information+for+additional+Important+Safety+Information&amp;index=13&amp;md5=c69c456b70fa3d97d94c592cbd007a7e\" rel=\"nofollow\" shape=\"rect\">full Prescribing Information for additional Important Safety Information<\/a>.<\/p><p>\n<b>Flyrcado\u2122 (flurpiridaz F 18 injection)\n<br\/><\/b><b>Indication and Usage:\n<br\/><\/b>Flyrcado is a radioactive diagnostic drug indicated for PET myocardial perfusion imaging (MPI) under rest or stress in adult patients with known or suspected coronary artery disease (CAD) to evaluate myocardial ischemia and infarction. <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2024%2F215168s000lbl.pdf&amp;esheet=54544245&amp;newsitemid=20260601878700&amp;lan=en-US&amp;anchor=%5Baccessdata.fda.gov%5D&amp;index=14&amp;md5=721428826df42de58477feb0f32df6b2\" rel=\"nofollow\" shape=\"rect\">[accessdata.fda.gov]<\/a><br\/><b>Contraindications:\n<br\/><\/b>None.\n<br\/><b>Adverse Reactions:\n<br\/><\/b>The most common adverse reactions occurring during FLYRCADO PET MPI under rest and stress (pharmacologic or exercise) (incidence \u2265 2%) are dyspnea, headache, angina pectoris, chest pain, fatigue, ST segment changes, flushing, nausea, abdominal pain, dizziness, and arrhythmia.<\/p><p>\nTo report SUSPECTED ADVERSE REACTIONS, contact GE HealthCare at 800-654-0118 or the FDA at 800-FDA-1088 or <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.fda.gov%2Fmedwatch&amp;esheet=54544245&amp;newsitemid=20260601878700&amp;lan=en-US&amp;anchor=www.fda.gov%2Fmedwatch&amp;index=15&amp;md5=362fd106ff1331f7efb09853ea300316\" rel=\"nofollow\" shape=\"rect\">www.fda.gov\/medwatch<\/a>.\n<br\/>For full prescribing information, <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.gehealthcare.com%2F-%2Fjssmedia%2Fgehc%2Fus%2Ffiles%2Fproducts%2Fnuclear-imaging-agents%2Fflyrcado%2Fflyrcado-pi.pdf%3Frev%3D-1&amp;esheet=54544245&amp;newsitemid=20260601878700&amp;lan=en-US&amp;anchor=click+here&amp;index=16&amp;md5=4417c16bc485e3a71a8a6eeac48d992c\" rel=\"nofollow\" shape=\"rect\">click here<\/a>. For important safety information, please <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.gehealthcare.com%2F-%2Fjssmedia%2Fgehc%2Fus%2Ffiles%2Fproducts%2Fflyrcado%2Fflyrcado-important-safety-information.pdf%3Frev%3D-1&amp;esheet=54544245&amp;newsitemid=20260601878700&amp;lan=en-US&amp;anchor=click+here&amp;index=17&amp;md5=0505b51f126ba7934d69cbdb1150d83f\" rel=\"nofollow\" shape=\"rect\">click here<\/a>.<\/p><p>\n<b>Vizamyl\u2122 (flutemetamol F 18 injection)\n<br\/><\/b><b>Indication and Usage:\n<br\/><\/b>VIZAMYL\u2122 (flutemetamol F 18 injection) is indicated for positron-emission tomography (PET) of the brain to estimate amyloid beta neuritic plaque density in adults with cognitive impairment for: evaluation of Alzheimer\u2019s disease (AD) and other causes of cognitive decline; and selection of patients who are indicated for amyloid beta-directed therapy as described in the prescribing information of the therapeutic products\n<br\/><b>Contraindications:\n<br\/><\/b>Known hypersensitivity to Vizamyl or any excipient, including polysorbate 80.\n<br\/><b>Adverse Reactions:\n<br\/><\/b>The most commonly reported adverse reactions in clinical trials were flushing (2%), increased blood pressure (2%), headache (1%), nausea and dizziness (1%). Post marketing experience included anaphylactic reactions. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a casual relationship to drug exposure.<\/p><p>\nTo report SUSPECTED ADVERSE REACTIONS, contact GE HealthCare at 800-654-0118 or the FDA at 800-FDA-1088 or <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.fda.gov%2Fmedwatch&amp;esheet=54544245&amp;newsitemid=20260601878700&amp;lan=en-US&amp;anchor=www.fda.gov%2Fmedwatch&amp;index=18&amp;md5=d8e8b4c567b6ba1dcca33b2a34c491f9\" rel=\"nofollow\" shape=\"rect\">www.fda.gov\/medwatch<\/a>.\n<br\/>For full prescribing information, please visit:\n<br\/><a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.gehealthcare.com%2Fcontent%2Fdam%2Fgehc%2Fglobal%2Fproducts%2Fmolecular-imaging-agents%2Fvizamyl%2Fdocuments%2Fer-clinical-product-pi-en.pdf&amp;esheet=54544245&amp;newsitemid=20260601878700&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.gehealthcare.com%2Fcontent%2Fdam%2Fgehc%2Fglobal%2Fproducts%2Fmolecular-imaging-agents%2Fvizamyl%2Fdocuments%2Fer-clinical-product-pi-en.pdf&amp;index=19&amp;md5=833383a5a00428059b5ee2b7ed078f62\" rel=\"nofollow\" shape=\"rect\">https:\/\/www.gehealthcare.com\/content\/dam\/gehc\/global\/products\/molecular-imaging-agents\/vizamyl\/documents\/er-clinical-product-pi-en.pdf<\/a><\/p><table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth100\">\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwwidth100\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nMay 2026 JB14025US<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwpadl0 bwwidth100\" colspan=\"1\" rowspan=\"1\">_____________________<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwwidth100\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<sup>i<\/sup> Ezhilarasan, E., Sabarees, G. &amp; Premkumar, P.P. Radioligand theranostics in oncology: emerging trends in target design and radiochemical innovation. J Radioanal Nucl Chem (2026). <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs10967-026-10891-3&amp;esheet=54544245&amp;newsitemid=20260601878700&amp;lan=en-US&amp;anchor=https%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs10967-026-10891-3&amp;index=20&amp;md5=bf23d9d7145122e7bc2f2cc82f120c43\" rel=\"nofollow\" shape=\"rect\">https:\/\/link.springer.com\/article\/10.1007\/s10967-026-10891-3<\/a>.<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwwidth100\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<sup>ii<\/sup> Research and Markets. <i>Radiopharmaceuticals Market Report 2026<\/i>. Dublin: Research and Markets, 2026. <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.researchandmarkets.com%2Freports%2F5939063%2Fradiopharmaceuticals-market-report&amp;esheet=54544245&amp;newsitemid=20260601878700&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.researchandmarkets.com%2Freports%2F5939063%2Fradiopharmaceuticals-market-report&amp;index=21&amp;md5=6d9055e8c23a4601b0dd5e9b9ecec6b0\" rel=\"nofollow\" shape=\"rect\">https:\/\/www.researchandmarkets.com\/reports\/5939063\/radiopharmaceuticals-market-report<\/a>.<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwwidth100\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<sup>iii<\/sup> Global Market Insights. U.S. Nuclear Medicine Market Size &amp; Share, 2025\u20132034. Published October 2025. Accessed May 4, 2026. <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.gminsights.com%2Findustry-analysis%2Fus-nuclear-medicine-market&amp;esheet=54544245&amp;newsitemid=20260601878700&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.gminsights.com%2Findustry-analysis%2Fus-nuclear-medicine-market&amp;index=22&amp;md5=55a2154944c1dcd1fde34cf534aa75be\" rel=\"nofollow\" shape=\"rect\">https:\/\/www.gminsights.com\/industry-analysis\/us-nuclear-medicine-market<\/a>.<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwwidth100\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<sup>iv<\/sup> Global Market Insights. <i>Nuclear Medicine Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025\u20132034<\/i>. Published October 8, 2025. Accessed April 16, 2026. <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.giiresearch.com%2Freport%2Fgmi1858986-nuclear-medicine-market-opportunity-growth-drivers.html%3Futm_source%3Dchatgpt.com&amp;esheet=54544245&amp;newsitemid=20260601878700&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.giiresearch.com%2Freport%2Fgmi1858986-nuclear-medicine-market-opportunity-growth-drivers.html%3Futm_source%3Dchatgpt.com&amp;index=23&amp;md5=e3547c8e614693993c5b840acc8bc795\" rel=\"nofollow\" shape=\"rect\">https:\/\/www.giiresearch.com\/report\/gmi1858986-nuclear-medicine-market-opportunity-growth-drivers.html?utm_source=chatgpt.com<\/a><\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwwidth100\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<sup>v<\/sup> Grand View Research. <i>U.S. Alzheimer\u2019s Disease Diagnostics Market Report, 2030<\/i>. San Francisco: Grand View Research, 2025. <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.grandviewresearch.com%2Findustry-analysis%2Fus-alzheimers-disease-diagnostics-market-report&amp;esheet=54544245&amp;newsitemid=20260601878700&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.grandviewresearch.com%2Findustry-analysis%2Fus-alzheimers-disease-diagnostics-market-report&amp;index=24&amp;md5=191cc3f19d0a0662e84f71a9f451201f\" rel=\"nofollow\" shape=\"rect\">https:\/\/www.grandviewresearch.com\/industry-analysis\/us-alzheimers-disease-diagnostics-market-report<\/a>.<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwwidth100\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<sup>vi<\/sup> MIM KineticID is 510(k)-pending with the U.S. FDA. Not CE Marked. Not available for sale in the United States, Europe, Canada, or any other region.<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwwidth100\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<sup>vii<\/sup> GE HealthCare data on file.<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwwidth100\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<sup>viii<\/sup> Up to 53% reduction of PET scan time on Omni Legend 32 cm compared to Discovery MI 25 cm, as demonstrated in phantom testing.<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwwidth100\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<sup>ix<\/sup> Omni Legend 32 cm increases small lesion detectability 16% on average and up to 20%, as compared to Discovery MI 25 cm with matched scan time\/injected dose, as demonstrated in phantom testing using a model observer with 4 mm lesions; average of different reconstruction methods.<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwwidth100\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<sup>x<\/sup> MINItrace Magni is technology in development. Not CE marked.<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwwidth100\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<sup>xi<\/sup> Global Market Insights. <i>Nuclear Medicine Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025\u20132034<\/i>. Published October 8, 2025. Accessed April 16, 2026. <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.giiresearch.com%2Freport%2Fgmi1858986-nuclear-medicine-market-opportunity-growth-drivers.html%3Futm_source%3Dchatgpt.com&amp;esheet=54544245&amp;newsitemid=20260601878700&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.giiresearch.com%2Freport%2Fgmi1858986-nuclear-medicine-market-opportunity-growth-drivers.html%3Futm_source%3Dchatgpt.com&amp;index=25&amp;md5=e164edc0cec2a0ac8f4b06385f53a9be\" rel=\"nofollow\" shape=\"rect\">https:\/\/www.giiresearch.com\/report\/gmi1858986-nuclear-medicine-market-opportunity-growth-drivers.html?utm_source=chatgpt.com<\/a><\/p><\/td><\/tr>\n<\/table><p>\n\u00a0<\/p><br\/> <b>Contacts<\/b> <br\/><p>\n<b>GE HealthCare Media Contact:<\/b><br\/>Margaret Steinhafel\n<br\/>M +1 608 381 8829\n<br\/><a  href=\"mailto:margaret.steinhafel@gehealthcare.com\" rel=\"nofollow\" shape=\"rect\">margaret.steinhafel@gehealthcare.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Nuclear medicine is reaching an inflection point as advances in imaging, theranostics and radiopharmaceuticals help accelerate clinical adoption<\/p>\n<p>At #SNMMI26, GE HealthCare is showcasing solutions designed to expand access, streamline workflows and s&#8230;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-13852","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/13852","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=13852"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/13852\/revisions"}],"predecessor-version":[{"id":13853,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/13852\/revisions\/13853"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=13852"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=13852"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=13852"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}